Editorial_Board | Journal of Crohn's and Colitis | Oxford Academic
PDF) Budesonide is superior to mesalazine in maintaining disease remission for patients with steroid-dependent Crohn's disease | Gerassimos Mantzaris - Academia.edu
s of ECCO
Clinical profiles of moderate and severe Crohn's disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines. - Abstract - Europe PMC
Editorial_Board | Journal of Crohn's and Colitis | Oxford Academic
iBDNEWS#1/14
Tibor HLAVATY | Senior gastroenterologist | MD, PhD, Assoc. Prof | Department of internal medicine V. | Research profile
PDF) The histopathological approach to inflammatory bowel disease: A practice guide
Editorial_Board | Journal of Crohn's and Colitis | Oxford Academic
PDF) Oral azathioprine for steroid refractory severe ulcerative colitis | Gerassimos Mantzaris - Academia.edu
Editorial_Board | Journal of Crohn's and Colitis | Oxford Academic
PDF) Prevalence and Characteristics of Extra-intestinal Manifestations in a Large Cohort of Greek Patients with Inflammatory Bowel Disease
Inflammatory Bowel Diseases
ECCO in Vienna was the Best Congress Ever!
Untitled
ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease—An Update
Editorial_Board | Journal of Crohn's and Colitis | Oxford Academic
European Crohn´s and Colitis Organisation - ECCO - Uncategorised
Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Resul
ECCO in Vienna was the Best Congress Ever!
ECCO
European Crohn´s and Colitis Organisation - ECCO - The Council of National Representatives
A continued story of success: Feeding science, digesting knowledge
Γεράσιμος Μάντζαρης: «Ύφεση νόσου με ασφαλή και αποτελεσματικά φάρμακα» - Hellenic Medical Review
European Crohn´s and Colitis Organisation - ECCO - The Council of National Representatives
Editorial_Board | Journal of Crohn's and Colitis | Oxford Academic
